AR056551A1 - Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica - Google Patents
Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpeticaInfo
- Publication number
- AR056551A1 AR056551A1 ARP060104294A ARP060104294A AR056551A1 AR 056551 A1 AR056551 A1 AR 056551A1 AR P060104294 A ARP060104294 A AR P060104294A AR P060104294 A ARP060104294 A AR P060104294A AR 056551 A1 AR056551 A1 AR 056551A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- hsv
- brivudine
- ophthalmic composition
- steroid
- Prior art date
Links
- 229960001169 brivudine Drugs 0.000 title abstract 3
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 229920000058 polyacrylate Polymers 0.000 abstract 2
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 208000025889 stromal keratitis Diseases 0.000 abstract 2
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 abstract 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 abstract 1
- 229960002390 flurbiprofen Drugs 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 229960002800 prednisolone acetate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones farmacéuticas que contienen el antiviral brivudina, utiles para el tratamiento de condiciones inflamatorias oculares, particularmente la queratitis estromal inducida por el Virus del Herpes Simple Tipo 1 (HSV-1) o por el Virus de la Varicela-Zoster(VZV). Reivindicacion 1: Composicion oftálmica caracterizada porque contiene brivudina como principio activo y un agente formador de película seleccionado del grupo que consiste en polivinilpirrolidona (PVP), alcohol polivinílico (PVA) y poliacrilato (PA). Reivindicacion 14: Una preparacion combinada, caracterizada porque contiene una composicion oftálmica de acuerdo con las reivindicaciones 1-13 y una droga antiinflamatoria esteroide o no esteroide para uso simultáneo, sucesivo o separado en el tratamiento de enfermedades oculares. Reivindicacion 15: Una preparacion combinada de acuerdo con la reivindicacion 14, caracterizada porque el esteroide es prednisolona acetato o flurometolona y la droga antiinflamatoria no esteroide es flurbiprofeno. Reivindicacion 16: El uso de una composicion oftálmica de acuerdo con las reivindicaciones 1-13, caracterizado porque es para la preparacion de un medicamento para el tratamiento de la queratitis epitelial por HSV, queratitis estromal por HSV, complicaciones oculares del herpes zoster oftálmico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005046769A DE102005046769A1 (de) | 2005-09-29 | 2005-09-29 | Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056551A1 true AR056551A1 (es) | 2007-10-10 |
Family
ID=37561306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104294A AR056551A1 (es) | 2005-09-29 | 2006-09-28 | Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20080249061A1 (es) |
| EP (1) | EP1940353B1 (es) |
| JP (1) | JP2009509993A (es) |
| KR (1) | KR20080053319A (es) |
| CN (1) | CN101272765A (es) |
| AP (1) | AP2008004394A0 (es) |
| AR (1) | AR056551A1 (es) |
| AT (1) | ATE489076T1 (es) |
| AU (1) | AU2006299115A1 (es) |
| BR (1) | BRPI0616449A2 (es) |
| CA (1) | CA2624111A1 (es) |
| CR (1) | CR9839A (es) |
| CY (1) | CY1111059T1 (es) |
| DE (2) | DE102005046769A1 (es) |
| DK (1) | DK1940353T3 (es) |
| EA (1) | EA012975B1 (es) |
| EC (1) | ECSP088310A (es) |
| ES (1) | ES2356774T3 (es) |
| HN (1) | HN2008000497A (es) |
| HR (1) | HRP20110085T1 (es) |
| IL (1) | IL190466A0 (es) |
| MA (1) | MA29887B1 (es) |
| NO (1) | NO20081488L (es) |
| PE (1) | PE20070767A1 (es) |
| PL (1) | PL1940353T3 (es) |
| PT (1) | PT1940353E (es) |
| RS (1) | RS51615B (es) |
| SI (1) | SI1940353T1 (es) |
| TN (1) | TNSN08094A1 (es) |
| TW (1) | TW200744664A (es) |
| UA (1) | UA90911C2 (es) |
| WO (1) | WO2007039201A2 (es) |
| ZA (1) | ZA200802729B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
| US20090196833A1 (en) * | 2008-02-06 | 2009-08-06 | Adherex Technologies Inc. | Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome |
| DE102009003942A1 (de) * | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
| PT2898888T (pt) | 2014-01-22 | 2019-07-16 | Visufarma B V | Composição que compreende iota-carragenina contra conjuntivite viral |
| BR112018072647A2 (pt) * | 2016-05-06 | 2019-02-19 | SaCSh Corp. | composições oftálmicas |
| CN113712928A (zh) * | 2021-09-29 | 2021-11-30 | 重庆市力扬医药开发有限公司 | 经口腔粘膜吸收的溴夫定药物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY136633A (en) * | 2001-01-17 | 2008-11-28 | Berlin Chemie Ag | Stabilized brivudine topical formulations |
| DE10162593A1 (de) * | 2001-12-19 | 2003-07-03 | Menarini Ricerche Spa | Stabilisierte topische Brivudin-Formulierungen |
-
2005
- 2005-09-29 DE DE102005046769A patent/DE102005046769A1/de not_active Withdrawn
-
2006
- 2006-09-27 EP EP06805904A patent/EP1940353B1/en active Active
- 2006-09-27 KR KR1020087007483A patent/KR20080053319A/ko not_active Application Discontinuation
- 2006-09-27 AT AT06805904T patent/ATE489076T1/de active
- 2006-09-27 CN CNA2006800356965A patent/CN101272765A/zh active Pending
- 2006-09-27 JP JP2008532659A patent/JP2009509993A/ja not_active Withdrawn
- 2006-09-27 DK DK06805904.7T patent/DK1940353T3/da active
- 2006-09-27 SI SI200630913T patent/SI1940353T1/sl unknown
- 2006-09-27 ZA ZA200802729A patent/ZA200802729B/xx unknown
- 2006-09-27 CA CA002624111A patent/CA2624111A1/en not_active Abandoned
- 2006-09-27 PT PT06805904T patent/PT1940353E/pt unknown
- 2006-09-27 PL PL06805904T patent/PL1940353T3/pl unknown
- 2006-09-27 AP AP2008004394A patent/AP2008004394A0/xx unknown
- 2006-09-27 EA EA200800646A patent/EA012975B1/ru not_active IP Right Cessation
- 2006-09-27 BR BRPI0616449-8A patent/BRPI0616449A2/pt not_active IP Right Cessation
- 2006-09-27 RS RS20110016A patent/RS51615B/en unknown
- 2006-09-27 TW TW095135667A patent/TW200744664A/zh unknown
- 2006-09-27 US US12/088,397 patent/US20080249061A1/en not_active Abandoned
- 2006-09-27 UA UAA200802782A patent/UA90911C2/ru unknown
- 2006-09-27 AU AU2006299115A patent/AU2006299115A1/en not_active Abandoned
- 2006-09-27 ES ES06805904T patent/ES2356774T3/es active Active
- 2006-09-27 WO PCT/EP2006/009383 patent/WO2007039201A2/en active Application Filing
- 2006-09-27 DE DE602006018505T patent/DE602006018505D1/de active Active
- 2006-09-28 PE PE2006001181A patent/PE20070767A1/es not_active Application Discontinuation
- 2006-09-28 AR ARP060104294A patent/AR056551A1/es unknown
-
2008
- 2008-02-28 TN TNP2008000094A patent/TNSN08094A1/en unknown
- 2008-03-25 EC EC2008008310A patent/ECSP088310A/es unknown
- 2008-03-26 NO NO20081488A patent/NO20081488L/no not_active Application Discontinuation
- 2008-03-27 IL IL190466A patent/IL190466A0/en unknown
- 2008-03-27 CR CR9839A patent/CR9839A/es not_active Application Discontinuation
- 2008-03-27 HN HN2008000497A patent/HN2008000497A/es unknown
- 2008-04-24 MA MA30877A patent/MA29887B1/fr unknown
-
2010
- 2010-12-23 CY CY20101101189T patent/CY1111059T1/el unknown
-
2011
- 2011-02-03 HR HR20110085T patent/HRP20110085T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056551A1 (es) | Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica | |
| Tsatsos et al. | Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents | |
| DOP2006000110A (es) | Composición farmaceútica que contiene gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato | |
| CL2013003016A1 (es) | Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco. | |
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| ES2688297T3 (es) | Gotas oculares antivíricas | |
| AR038455A1 (es) | Brivudina estabilizada en formulaciones topicas | |
| Abdel-Haq et al. | New antiviral agents | |
| WO2015167368A1 (en) | 4, 6-di (3,12-diaza-6, 9-diazoniadispiro [5.2.5.2] hexandecan-1-yl) -2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate for the treatment of herpetic infection and a topical pharmaceutical composition | |
| AU2014230133A1 (en) | Antiviral indolo(2,3-b)quinoxaline | |
| US9789107B2 (en) | Pharmaceutical formulation comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-B)quinoxaline | |
| RU2533232C2 (ru) | Применение поликарбоксильного производного фуллерена в качестве микробицидного противовирусного средства | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| PE20231946A1 (es) | Formulacion solida | |
| WO2013067409A1 (en) | Antimicrobial carboline compounds | |
| AR082054A1 (es) | Derivados aril- y heteroarilamida como inhibidor de enzima pde10a | |
| GB2310139A (en) | Preparations for the treatment of recurrent herpetic lesions | |
| BR112015014180A8 (pt) | composições de gel | |
| EP4365299A3 (en) | Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease | |
| ECSP045210A (es) | 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco | |
| AR064544A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular | |
| US20080287470A1 (en) | Presentation of an Antiviral Pharmaceutical Composition | |
| UY30848A1 (es) | Uso de derivados de mononitrato de dianhidrohexita?? como agentes reductores de la hipertension ocular | |
| Terasawa et al. | Intraoral pseudotumor of lower lip mucosa due to cytomegalovirus infection after bone marrow transplantation in a leukemia patient: A case report | |
| RU2015155741A (ru) | Антибактериальные порошки на основе отрицательно заряженного диоксида кремния или титана, на котором адсорбированы фармацевтически активные катионы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |